Pre-Made Insulin Biosimilar, Recombinant Protein targeting INSR: Recombinant therapeutic protein targeting CD220/HHF5 for drug discovery and mechanism of action (MOA) research

Pre-Made Insulin Biosimilar, Recombinant Protein targeting INSR: Recombinant therapeutic protein targeting CD220/HHF5 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Insulin is a peptide hormone produced by beta cells of the pancreatic islets; it is considered to be the main anabolic hormone of the body. It regulates the metabolism of carbohydrates, fats and protein by promoting the absorption of glucose from the blood into liver, fat and skeletal muscle cells. Insulin therapy is often an important part of diabetes treatment.